Showing results (11-20 of 2,196) with videos related to
Sort By:
Pageof 220
Pharmacological Reviews|February 15, 2001
The control of prostate-specific antigen expression and gene regulation by pharmacological agentsS C Dixon, K B Knopf, W D FiggThe Journal of Pathology|October 10, 2001
The androgen receptor gene and its influence on the development and progression of prostate cancerJ S Montgomery, D K Price, W D FiggBiomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 12, 2002
Thalidomide, an antiangiogenic agent with clinical activity in cancerS S W Ng, M Brown, W D FiggCancer Research|November 4, 2000
Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancerK Salnikow, M Costa, W D Figg, et al.Molecular Pharmacology|June 1, 1995
Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cellsR Danesi, W D Figg, E Reed, et al.Journal of Chromatography. B, Biomedical Sciences and Applications|August 14, 2001
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometryE W Woo, R Messmann, E A Sausville, et al.Oncology Reports|June 19, 1998
A phase II study of bromocriptine in patients with androgen-independent prostate cancerJ Horti, W D Figg, B Weinberger, et al.Neoplasma|August 31, 1999
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinomaI N Arah, S C Dixon, J Horti, et al.International Journal of Oncology|March 17, 2001
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell linesM V Blagosklonny, S C Dixon, R Robey, et al.Urology|August 11, 1998
Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancerO Sartor, M Weinberger, A Moore, et al.Pageof 220